Pulmatrix secures $30.2 million for respiratory candidates
04 November 2009
Christopher Spillane
Please Login to read the full article.
04 November 2009
Christopher Spillane
christopher.spillane@informausa.com
Pulmatrix will advance its new class of host-targeted therapies for respiratory disease after raising $30.2 million from private investors.
The funds will be used to begin several clinical trials in 2010-11 across a range of respiratory diseases. Pulmatrix's CEO
Robert Connelly said that...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Selecta, Bind gain $94.5 million for nanoparticle R&D, $50M from Rusnano
- US Capitol Capsule: Will sequestration be a better outcome for biopharma?
- TopiVert raises £8 million from Imperial Innovations and SV Life Sciences
- Hunter to merge with Probiomics as it seeks partner for Phase II COPD vaccine
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
